Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lindsey Pennington

Facial Plastic Surgery Shreveport, LA Medical Doctor

NPI 1134411507 CMS profile 1390643

1501 Kings Hwy, Otolaryngology, Shreveport, LA 71103

Open in the dashboard

General payments

$420,220

497 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lindsey Pennington of Shreveport, LA is reported in the CMS Open Payments database as having received $420,220 across 497 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47,705 72
2024 General $134,472 135
2023 General $163,225 121
2022 General $38,916 81
2021 General $35,414 54
2020 General $171 10
2019 General $317 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lindsey Pennington
  • Facial Plastic Surgery median
  • Middle half of Facial Plastic Surgery
  • National median

In program year 2025, general payments to Lindsey Pennington were reported at $47,705. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.

Show as a table
Year Lindsey Pennington Facial Plastic Surgery median Middle half National median
2019 $317 $225 $92–$651 $163
2020 $171 $132 $45–$323 $114
2021 $35,414 $186 $67–$558 $132
2022 $38,916 $218 $83–$594 $149
2023 $163,225 $237 $94–$564 $160
2024 $134,472 $233 $104–$575 $164
2025 $47,705 $270 $116–$579 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $295,836 269 payments
  2. Galderma Laboratories, L.P. $84,595 92 payments
  3. Allergan Inc. $39,580 133 payments
  4. Revance Therapeutics, Inc. $95 1 payment
  5. Merz North America, Inc. $87 1 payment
  6. Dutch Ophthalmic, USA $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $374,825 120 payments
  2. Travel and Lodging $25,879 95 payments
  3. Consulting Fee $11,400 2 payments
  4. Food and Beverage $8,072 275 payments
  5. Education $45 5 payments
Products named General payments · program years 2019–2025
  1. BOTOX $138,143 127 payments
  2. KYBELLA $1,950 1 payment
  3. DYSPORT $197 12 payments
  4. DAXXIFY $95 1 payment
  5. DYSPORT $72 5 payments
  6. TISSUEBLUE $26 1 payment
  7. EVA, combined machine $26 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

68

Median for Otolaryngology: 297

Drug cost

$1,054

Median for Otolaryngology: $6,314

Branded share of claims

44.1%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 12 $363
Cephalexin Generic 11 $214
Valacyclovir Valacyclovir Hcl Brand 17 $177
Ondansetron Odt Ondansetron Brand 13 $158
Mupirocin Generic 15 $142

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $34,657
$34,657 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $95
$95 — —
DYSPORT
  • Galderma Laboratories, L.P. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

497 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Facial Plastic Surgery in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record